Bruker Unveils Advanced Proteomics Workflows for Drug Discovery and Disease Research
Event summary
- Bruker introduced timsUltra AIP and timsOmni workflows at the Human Proteome Organization World Congress 2026, enhancing protein-sequence coverage and structural analysis.
- Multi-enzyme dia-PASEF workflow yielded ~350,000 peptides per sample in Parkinson’s brain samples, identifying ~14,500 protein isoforms.
- ProteoScape workflows enable direct transition from discovery to target validation on the same timsTOF platform.
- Spectronaut v21 uses AI transfer learning to adapt to new mass spectrometry capabilities dynamically.
- Bruker and Affipro Analytics partnered to integrate HDX-MS workflows for structural proteomics.
The big picture
Bruker’s new proteomics workflows aim to deepen protein-sequence coverage and structural analysis, addressing critical needs in drug discovery and disease research. The advancements in AI-driven mass spectrometry and partnerships with academic institutions highlight the company’s strategic focus on enhancing biological AI models. These innovations position Bruker as a key player in the post-genomic era, potentially influencing the broader biotechnology and pharmaceutical sectors.
What we're watching
- Technological Integration
- How Bruker’s integration of AI transfer learning in Spectronaut v21 will accelerate adaptation to new mass spectrometry technologies.
- Market Adoption
- Whether the advanced proteomics workflows will drive significant adoption in drug discovery and disease biology research.
- Partnership Impact
- The pace at which Bruker’s partnership with Affipro Analytics will enhance structural proteomics capabilities.
Related topics